REGENXBIO Inc. (RGNX): Price and Financial Metrics

REGENXBIO Inc. (RGNX): $17.11

0.51 (-2.89%)

POWR Rating

Component Grades








Add RGNX to Watchlist
Sign Up

Industry: Biotech




#96 of 359

in industry

RGNX Price/Volume Stats

Current price $17.11 52-week high $27.20
Prev. close $17.62 52-week low $16.93
Day low $17.10 Volume 363,900
Day high $17.62 Avg. volume 388,929
50-day MA $18.00 Dividend yield N/A
200-day MA $20.16 Market Cap 752.16M

RGNX Stock Price Chart Interactive Chart >


  • Value is the dimension where RGNX ranks best; there it ranks ahead of 70.29% of US stocks.
  • The strongest trend for RGNX is in Quality, which has been heading up over the past 179 days.
  • RGNX ranks lowest in Sentiment; there it ranks in the 8th percentile.

RGNX Stock Summary

  • Of note is the ratio of REGENXBIO INC's sales and general administrative expense to its total operating expenses; merely 11.66% of US stocks have a lower such ratio.
  • In terms of twelve month growth in earnings before interest and taxes, REGENXBIO INC is reporting a growth rate of -299.62%; that's higher than merely 5.06% of US stocks.
  • As for revenue growth, note that RGNX's revenue has grown -79.98% over the past 12 months; that beats the revenue growth of merely 2.15% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to REGENXBIO INC are SELB, TSVT, ENTA, VIR, and STRO.
  • Visit RGNX's SEC page to see the company's official filings. To visit the company's web site, go to

RGNX Valuation Summary

  • In comparison to the median Healthcare stock, RGNX's price/earnings ratio is 110.64% lower, now standing at -2.9.
  • Over the past 97 months, RGNX's price/sales ratio has gone down 197.7.

Below are key valuation metrics over time for RGNX.

Stock Date P/S P/B P/E EV/EBIT
RGNX 2023-09-18 8.1 1.9 -2.9 -3.1
RGNX 2023-09-15 8.1 1.9 -2.9 -3.1
RGNX 2023-09-14 8.2 2.0 -2.9 -3.1
RGNX 2023-09-13 8.2 2.0 -2.9 -3.1
RGNX 2023-09-12 7.9 1.9 -2.8 -3.0
RGNX 2023-09-11 7.8 1.9 -2.8 -3.0

RGNX Growth Metrics

    The year over year net cashflow from operations growth rate now stands at 442.33%.
  • Its year over year revenue growth rate is now at 204.02%.
  • The 5 year revenue growth rate now stands at 1017.89%.
RGNX's revenue has moved up $444,801,000 over the prior 33 months.

The table below shows RGNX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 480.034 158.121 73.637
2022-06-30 484.295 172.218 90.716
2022-03-31 473.681 204.095 101.256
2021-12-31 470.347 218.875 127.84
2021-09-30 93.137 -67.894 -212.424
2021-06-30 161.276 -67.995 -145.228

RGNX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RGNX has a Quality Grade of D, ranking ahead of 18.52% of graded US stocks.
  • RGNX's asset turnover comes in at 0.116 -- ranking 250th of 682 Pharmaceutical Products stocks.
  • PTGX, ARDX, and CBAY are the stocks whose asset turnover ratios are most correlated with RGNX.

The table below shows RGNX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.116 0.581 -0.362
2021-06-30 0.218 0.738 -0.257
2021-03-31 0.242 0.762 -0.255
2020-12-31 0.286 0.769 -0.281
2020-09-30 0.297 0.798 -0.244
2020-06-30 0.126 0.763 -0.367

RGNX Price Target

For more insight on analysts targets of RGNX, see our RGNX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $64.00 Average Broker Recommendation 1.5 (Moderate Buy)

REGENXBIO Inc. (RGNX) Company Bio

REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The company was founded in 2009 and is based in Rockville, Maryland.

RGNX Latest News Stream

Event/Time News Detail
Loading, please wait...

RGNX Latest Social Stream

Loading social stream, please wait...

View Full RGNX Social Stream

Latest RGNX News From Around the Web

Below are the latest news stories about REGENXBIO INC that investors may wish to consider to help them evaluate RGNX as an investment opportunity.

We're Keeping An Eye On REGENXBIO's (NASDAQ:RGNX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | September 22, 2023

REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:

Yahoo | September 5, 2023

Initial Clinical Data of First Pediatric CLN2 Patient Dosed with RGX-181 Presented at SSIEM Annual Symposium

REGENXBIO Inc. (Nasdaq: RGNX) today announced that initial interim data from a first-in-human single-patient, investigator-initiated trial of RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, a form of Batten disease, were presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium in Jerusalem.

Yahoo | August 30, 2023

REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023

REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023 in Jerusalem, Israel (August 29 – September 1). Investigators will deliver encore presentations of interim clinical trial data from REGENXBIO's pipeline of one-time investigational AAV Therapeutics for progressive, neurodegenerative lysosomal storage disorders, as well as initial interim data from the single-patient, investigator-initiated study of RGX-181

Yahoo | August 23, 2023

Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of -31.75% and 49.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 2, 2023

Read More 'RGNX' Stories Here

RGNX Price Returns

1-mo -5.73%
3-mo -7.11%
6-mo -9.13%
1-year -25.15%
3-year -36.65%
5-year -76.69%
YTD -24.56%
2022 -30.64%
2021 -27.91%
2020 10.72%
2019 -2.34%
2018 26.17%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!